新浪登录
腾讯登录Luminex的xTAG技术将扩大疾病检测范围
| 导读 | 生物化验分析仪器公司 Luminex今天宣布其xTAG通用标签技术已经被选用于Assurex健康的GeneSight神经药物基因组学测试。 |
生物化验分析仪器公司 Luminex今天宣布其xTAG通用标签技术已经被选用于Assurex健康的GeneSight神经药物基因组学测试。
GeneSight测试通过已知的药理学知识对病人的DNA特征进行比对，对病人用药后的生理反应进行一定程度的预测。该项测试现阶段已经用于抑郁症、创伤后应激障碍、焦虑、双相情感障碍疾病、精神分裂症和其他行为性疾病的治疗。
根据 Luminex公司的报告，该公司的xTAG通用标签技术将加强GeneSight测试的运行速度与运行容量。与此同时，Assurex COO Donald Wright在声明中表示 ，因为具有极高的灵活性，Luminex的操作平台将允许Assurex的开发团队为GeneSight测试引入新的生物标志物，进一步扩大GeneSight测试的临床应用范围。合作的安排和具体条款没有在报告中披露。（转化医学网360zhyx.com）
以上为转化医学网原创翻译整理，如需转载，请联系 info@360zhyx.com 。原文：（genomeweb）
Luminex today announced that its xTAG universal tag technology has been selected for use in Assurex Health's GeneSight neuropsychiatric pharmacogenomics tests.
Gene Sight compares patients' DNA signatures with known pharmacology in order to predict how they might react to medicines used to treat depression, post-traumatic stress disorder, anxiety, bipolar disease, schizophrenia, and other behavioral health conditions.
According to Luminex, its technology will enhance the processing speed and capacity of the Gene Sight tests. "In addition, the flexibility of the Luminex platform will allow us to add new biomarkers as our needs continue to expand," Assurex COO Donald Wright said in a statement.
Specific terms of the arrangement were not disclosed.
还没有人评论，赶快抢个沙发